



**ASX Announcement | 28 January 2021  
Noxopharm Limited (ASX:NOX)**

## **Noxopharm To Present to ShareCafe “Hidden Gems” Webinar**

**28 January 2021 Sydney, Australia: Australian clinical stage drug development company, Noxopharm Limited (ASX:NOX),** provides a copy of the presentation to be made by the Company’s CEO and Managing Director, Dr Graham Kelly to the ShareCafe Micro/Small Cap “Hidden Gems” webinar series tomorrow, Friday 29 January 2021 from 12.30pm AEDT/9.30am AWST

To access further details and register for the event (no charge), please copy and paste the following link into your internet browser:

[https://us02web.zoom.us/webinar/register/WN\\_fNC67aP5SOWsDfz1F39ySg](https://us02web.zoom.us/webinar/register/WN_fNC67aP5SOWsDfz1F39ySg)

A recorded copy of the webinar will be made available following the event. A copy of the investor presentation to be delivered during the webinar is attached.

**-ENDS-**

*Graham Kelly, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.*

### **About Noxopharm**

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and cytokine release syndrome/septic shock.

Veyonda® is the Company’s first pipe-line drug candidate currently in Phase 2 clinical trialing. Veyonda® has two main drug actions – indirect inhibition of sphingosine kinase and STING signaling. The former function contributes to its dual-acting oncotoxic and immuno-oncology functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiotherapy and immune checkpoint inhibitors. The latter function provides an anti-inflammatory effect, also contributing to an anti-cancer action, but also blocking the cytokine release syndrome.

Noxopharm also is the major shareholder of US biotechnology company, Nyrada Inc (ASX:NYR).

To learn more, please visit: [noxopharm.com](http://noxopharm.com)

### **Investor & Corporate enquiries:**

Prue Kelly

M: 0459 022 445

E: [info@noxopharm.com](mailto:info@noxopharm.com)

### **Company Secretary:**

David Franks

T: +61 2 8072 1400

E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

**Media Enquiries**

Julia Maguire

The Capital Network

E: [julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)

T: + 61 2 8999 3699

**Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.



# Noxopharm Limited (ASX:NOX)

SHARE CAFE Hidden Gems

January 2021

Dr Graham Kelly  
CEO and Managing Director

Discover



Develop



Deliver



# Disclaimer



This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in NOX will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licenced to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

# Introduction to CEO *corporate track record*



Founded Market Peak market cap

Founded **Novogen**

1994

ASX; NASDAQ

**A\$880m** 2004

*[now Kazia Therapeutics ]*

~**A\$170m** 2021

Founded **Marshall Edwards Inc**

2002

NASDAQ

**A\$600m** 2003

*[now MEI Pharma Inc]*

~**A\$450m** 2021

Founded **Noxopharm Ltd**

2016

ASX

**A\$171m** 2021

Founded **Nyrada Inc**


2020

ASX

**A\$46m** 2021

# Key metrics


as at 27 January 2021



## News Flow (next 6 months)

- 3x Phase I/II and Phase II clinical cancer trials
- 1x COVID-19 clinical trial
- Growing first-in-class drug pipeline
- Pharmorage (subsidiary) dedicated to septic shock/autoimmune disease

# breakthrough multiple-acting immunotherapy drug





**Veyonda<sup>®</sup>**

## Clinical program



IONIC-1

Phase I/II trial

Veyonda + Opdivo<sup>®</sup> (**Bristol Myers Squibb**)

DARRT-2

Phase II trial

Veyonda + external radiotherapy

LuPIN-1

Phase II trial

Veyonda + <sup>177</sup>Lu-PSMA (**Novartis**)

NOXCOVID-1


Phase I/II trial

Veyonda



- IONIC-1 Phase I/II trial Veyonda + Opdivo<sup>®</sup> (**Bristol Myers Squibb**)
- DARRT-2 Phase II trial Veyonda + external radiotherapy
- **LuPIN-1** Phase I/II trial Veyonda + Lu-PSMA (**Novartis**)
- NOXCOVID-1 Phase I/II trial Veyonda + standard of care

# An exciting new treatment for prostate cancer



**<sup>177</sup>Lutetium-PSMA-617**. A radiopharmaceutical drug

Acquired by Novartis in 2018 in a ~**A\$9 billion** deal

A new treatment for prostate cancer once the cancer has spread widely and has stopped responding to chemotherapy

Drug injected intravenously to deliver a dose of radiation to all tumours throughout the body

# Late-stage prostate cancer rarely curable

## New treatments providing longer survival times urgently needed



Prostate cancer is the fifth leading cause of death in men worldwide


Responsible for estimated **360,000 deaths** in 2018

Mortality from prostate cancer **estimated to double by 2040**


**1.3 million new cases** reported worldwide in 2018

Exponential increase in death from prostate cancer with age

Source: Rawla P (2019) World J Oncol 10, 63-89



# LuPIN Study



As promising as  $^{177}\text{Lu}$ -PSMA-617 is, about one-third of men don't respond, and in those that do respond, they obtain (on average) about 6-8 months extra life

**QUESTION:** would adding Veyonda with its immunotherapy functions, boost the effectiveness of the Novartis drug, with more men responding as well as achieving significantly longer survival times?

Phase II study. St Vincent's Hospital Sydney. A/Prof Louise Emmett


56 men. Late-stage cancer. No remaining standard treatments. Anticipated survival 2-6 months (historical average 4.5 months)

6 cycles. 6 weeks apart.  $^{177}\text{Lu}$ -PSMA-617 (1 day) + Veyonda (14 days)

# LuPIN: Interim Survival Data



Median overall survival = time when half the patients have died and half still alive



1. NOX: data on file. 2. Hofman M et al (2018) Lancet Oncol 19, 825. 3. ASX announcement 14 Feb 2020

# LuPIN: Next Interim Data Reporting



American Society of Clinical Oncology

Genitourinary Cancers Symposium

Feb 11-13 2021

**32 men**

400 + 800 mg Veyonda

*Reported Feb 2020*

Median Overall Survival:

**17.1 months**

a remarkable result for this late stage of the disease

**Combination was well tolerated**

**56 men**

400 + 800 mg + 1200 mg

Veyonda

*To be reported Feb 2021*

Median Overall Survival:

**?? months**

**? A potential major breakthrough in the treatment of late-stage prostate Ca**

# Advanced prostate cancer: Attracting Significant Pharma Interest



Recent deals

2016

2018

2017

Price

US\$14 billion

US\$2.1 billion

US\$3.9 billion





## *For further information*

email: [info@noxopharm.com](mailto:info@noxopharm.com)

web: [www.noxopharm.com](http://www.noxopharm.com)

twitter: [@noxopharm](https://twitter.com/noxopharm)

Discover



Develop



Deliver

